NCT06752694 - Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions

Aplastic Anemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Transplantation

Undergo bone marrow transplant

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine

Given IV

DRUG

Granulocyte Colony-Stimulating Factor

Given SC

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo PBSC transplantation

DRUG

Ruxolitinib

Given PO

DRUG

Sirolimus

Given PO

RADIATION

Total-Body Irradiation

Undergo TBI

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Echocardiography

Undergo ECHO

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle